Top Markets
Coin of the day
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rang in Aktien #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Aktienkurs
$0.089
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$15.36M
Veränderung (1 Tag)
50.59%
Veränderung (1 Jahr)
111.85%
Land
US
Handel Inhibitor Therapeutics, Inc. (INTI)

Kategorie

Dividendenhistorie für Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (Aktienkürzel: INTI) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Inhibitor Therapeutics, Inc. (INTI) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH
29.00%
BE